Podcasts about Los Angeles

Patrick Reevell reports from Doha, the war in the Middle East intensifies with the U.S. and Israel reportedly trading strikes with Iran that appeared to target nuclear facilities; Jaclyn Lee reports from Los Angeles, the war and disruptions in the Strait of Hormuz are causing fuel prices to soar at the pump, and a major airline is cutting flights over skyrocketing costs; Selina Wang reports from the White House, President Trump threatens to send ICE agents to airports to help ease long delays at security as the partial government shutdown hits day 36 and more on tonight's broadcast of World News Tonight with David Muir.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Tim discusses the online rumor that Benjamin Netanyahu is no longer alive, watches Pete Hegseth try to explain the war in Iran, reads about a homeless man who fought a Waymo, tells Americans to stop traveling during the TSA shutdown, and listens to Donald Trump talk about taking Cuba.  Live Dates:

STREAMING THE MAKING OF THE JOHN BATCHELOR SHOW 3-20-20261868 PERSIAN GULFThis transcript from The John Bachelor Show features a dialogue between host John Bachelor, Jeff Bliss of Pacific Watch, and a commentator known as Germanicus. The discussion begins with an overview of California's current challenges, including record-breaking heatwaves and a controversial $100 million wildlife bridge in Agoura Hills that has faced significant budget overruns. The participants also examine the homelessness crisis in Los Angeles, specifically focusing on allegations of political fraud and the lack of financial accountability for state spending. Shifting to international affairs, the dialogue addresses rising global tensions involving Iran and the potential for infrastructure attacks that could destabilize energy markets. Finally, Germanicus provides a historical critique of modern American military strategy, arguing that the nation has traded versatile combat readiness for a reliance on expensive, "exquisite" weaponry.

SHOW SCHEDULE THE JOHN BATCHELOR 3-20-2-261939 OKLAHOMA1. California's Wildlife Bridge and the Homeless Crisis Guest: Jeff Bliss Summary: Jeff Bliss discusses the $100 million "Butterfly Bridge" in Agoura Hills, which is significantly over budget. He also details the "homeless industrial complex" in Los Angeles, including allegations of signature fraud and billions in missing funds. (2)2. The Billionaire Tax and California's Fiscal Deficit Guest: Jeff Bliss Summary: Bliss explores the proposed billionaire tax and the resulting exodus of capital to Florida and Texas. He examines Governor Newsom's national popularity despite a massive state budget deficit and local criticism of his leadership. (3)3. The Global Energy Crisis and Ground War Strategy Guest: Professor Richard Epstein Summary: Richard Epstein warns of a global energy crisis triggered by the Iran war, criticizing Europe's reliance on green energy. He argues that ground troops are necessary to sustain victory and hold military territory effectively. (4)4. UN Credibility and the Laws of Warfare Guest: Professor Richard Epstein Summary: Epstein critiques the UN Secretary-General for accusing Israel and the US of war crimes. He argues the UN lacks credibility and maintains that infrastructure remains a legitimate military target during times of war. (5)5. Lancaster's Pastry Economy and Infrastructure Progress Guest: Jim McTague Summary: Jim McTague observes Lancaster County's resilient economy, where residents seek "instant gratification" through French pastries during wartime. He also notes steady progress on local infrastructure projects, including a high-security data center. (6)6. Italian Judicial Reform and Tourism in Mantua Guest: Lorenzo Fiori Summary: Lorenzo Fiori explains a constitutional referendum regarding the separation of careers for magistrates and prosecutors. He also provides a travel guide to historic Mantua, recommending its medieval architecture, artichoke pasta, and regional wine. (7)7. Sector Optimism: Petroleum vs. the Housing Slump Guest: Gene Marks Summary: Gene Marks reports boom times for petroleum equipment manufacturers despite rising energy costs. Conversely, he notes that residential construction and home furnishings are struggling due to high interest rates and low buyer demand. (8)8. C-Corporation Tax Strategies and Microsoft AI Agents Guest: Gene Marks Summary: Gene Marks advises retiring entrepreneurs on converting businesses to C-corporations to avoid capital gains taxes. He also introduces Microsoft's new AI agents, which function like digital employees to automate routine administrative tasks. (9)9. Thomas Paine's Crisis and the Fabian Strategy Guest: Ed Larson Summary: Ed Larson details Thomas Paine's "American Crisis," which revitalized the patriot cause. He explains George Washington's "Fabian strategy" of tactical retreats to wear down the British army while their atrocities fueled local resistance. (10)10. Abigail Adams and the Limits of Equality Guest: Ed Larson Summary: This segment highlights Abigail Adams' plea to "remember the ladies" in the new code of laws. Ed Larson discusses how her husband, John Adams, dismissed these early calls for gender and racial equality. (11)11. Washington's Moral Victory at Trenton and Princeton Guest: Ed Larson Summary: Larson recounts Washington's daring crossing of the Delaware during a nor'easter. These victories at Trenton and Princeton provided a critical moral boost for the Continental Army, forcing the British out of West Jersey. (12)12. The Signing of Sovereignty and Revolutionary Dissent Guest: Ed Larson Summary: Details the signing of the Declaration of Independence and the adoption of radical state constitutions asserting that people alone are sovereign. Larson also explores honorable dissent through the perspective of wealthy planter John Dickinson. (13)13. WHO Nuclear Threat Warnings and Reactor Vulnerability Guest: Henry Sokolski Summary: Henry Sokolski analyzes World Health Organization preparations for a "worst-case scenario" nuclear incident. He highlights the vulnerability of regional power reactors to drone strikes and the resulting risks of large-scale radiological releases. (14)14. The Kharg Island Gambit and Vietnam Parallels Guest: Henry Sokolski Summary: Sokolski discusses reports that the US is considering an invasion of Iran's Kharg Island to reopen the Strait of Hormuz. He draws historical parallels to the initial 1965 escalation of the Vietnam War. (15)15. SpaceX Starship Milestones and Artemis Safety Risks Guest: Bob Zimmerman Summary: Reports on the upcoming 12th Starship test flight and Rocket Lab's military contracts. Zimmerman criticizes NASA's Artemis program for bypassing safety steps and risking lives with untested heat shields and life support. (16)16. Lunar Water Scarcity and Asteroid Ryugu Findings Guest: Bob Zimmerman Summary: Reviews scientific data suggesting significantly less water ice on the lunar South Pole than expected. Zimmerman also discusses the discovery of DNA building blocks on asteroid Ryugu and the ongoing sun dynamo mystery. (17)

In today's episode, I sit down with David Gastelum, founder of DASH, an AI-powered platform built to preserve the memories and stories that define a life. After 23 years as a Los Angeles firefighter responding to countless emergency calls, David began asking a powerful question: what happens to someone's memories after they're gone? That realization led him to create DASH, a digital legacy system that connects photos, videos, and personal stories to physical memorials using QR codes. We talk about honoring the people who shaped us, preserving family history beyond boxes of old photos, and how emerging technology may allow future generations to experience the voices, stories, and moments that shaped their lives.

The 49ers are not exercising left tackle Trent Williams' option bonus, per recent reports. All public-facing signs from San Francisco have signaled eventually coming to a reworked deal, but so far this offseason, those efforts haven't come to fruition. On this episode of 49ers Talk, Matt Maiocco breaks down what declining Trent Williams' option bonus means and how it affects their negotiations with their star offensive lineman moving forward. Later, Jennifer Lee Chan catches up with 49ers fullback Kyle Juszczyk from the Fanatics Flag Football Classic, where he joins other NFL stars and coach Kyle Shanahan at the same stadium that will host the event for the 2028 Summer Olympics in Los Angeles. -- (1:00) 49ers decline Trent Williams' option bonus (2:00) Breaking down how declining option affects 49ers' cap (10:00) Roster placeholders, draft prospects that could fill LT now and in the future (17:00) 49ers get much-needed leadership at WR group (20:00) 2026 Fanatics Flag Football Classic (30:00) Kyle Juszczyk interview Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Did the 2011 X-Men reboot set up the MCU with the way they're gonna introduce mutants in Spider-Man Brand New Day? Welcome back to THE ROAD TO DOOMSDAY, New Rockstars' ultimate Marvel rewatch podcast! In this episode, our hosts revisit the 2011 X-Men First Class film. Erik Voss and Jessica Clemons dive deep into Fox's reboot of X-Men franchise with First Class, and how the phrase “children of the atom” could end up being the roadmap for Marvel Studios in how mutants are unveiled in Spider-Man Brand New Day, Avengers Doomsday, Secret Wars, and X-Men! We're back at the UCB Theater in Los Angeles on April 17th, come in person or stream anywhere. Tickets: https://ucbcomedy.com/show/new-rockstars-live-its-morbin-time Join the NR Underground for exclusive audio shows: https://nrunderground.supercast.com Written by: Alex Berg Head of Content & Executive Producer: Erik Voss General Manager: Zach Huddleston Senior Producer: Jessica Clemons Producers: Gina Ippolito, Alex Berg, Patti Chambers Podcast Producer: Brian M Kim Post Production Supervisor: Joshua Steven Hurd Staff Editor: Abby Freel Editors: Eric Gorday For business inquiries please contact business@nrdigitalstudios.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Land Cinema in an Age of Extraction considers nonfiction filmmakers and film collectives whose work advances an understanding of land as a locus of social and environmental responsibility. Diving into little-known archives to explore films that resonate across geographies, Becca Voelcker unearths key examples of eco-political counterculture, from farmer-filmmakers in Japan and Mali to a gardener-filmmaker in Massachusetts, and from filmed landscape-portraits of women in Los Angeles, Orkney, and the Navajo Nation to Indigenous documentaries about land dispossession in Colombia. Proposing "land cinema" as an urgent genre for our time, this book reveals how images and ideas produced half a century ago sowed the seeds for climate justice movements today. Becca Voelcker is Lecturer in the Department of Art at Goldsmiths, University of London. She was named a BBC New Generation Thinker in 2024. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube Channel: here Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/film

⏰ 24-Hour Divorce Filing: What to Expect | Los Angeles Divorce Yes—you can file for divorce in Los Angeles within 24 hours. But filing fast does not mean the divorce is finalized in a day. California law still requires proper service, full disclosures, and a six-month waiting period before a divorce can be completed. This video explains what “24-hour filing” really means, what must be prepared in advance, and how organization—not shortcuts—makes fast filing possible.

Land Cinema in an Age of Extraction considers nonfiction filmmakers and film collectives whose work advances an understanding of land as a locus of social and environmental responsibility. Diving into little-known archives to explore films that resonate across geographies, Becca Voelcker unearths key examples of eco-political counterculture, from farmer-filmmakers in Japan and Mali to a gardener-filmmaker in Massachusetts, and from filmed landscape-portraits of women in Los Angeles, Orkney, and the Navajo Nation to Indigenous documentaries about land dispossession in Colombia. Proposing "land cinema" as an urgent genre for our time, this book reveals how images and ideas produced half a century ago sowed the seeds for climate justice movements today. Becca Voelcker is Lecturer in the Department of Art at Goldsmiths, University of London. She was named a BBC New Generation Thinker in 2024. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube Channel: here Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

Land Cinema in an Age of Extraction considers nonfiction filmmakers and film collectives whose work advances an understanding of land as a locus of social and environmental responsibility. Diving into little-known archives to explore films that resonate across geographies, Becca Voelcker unearths key examples of eco-political counterculture, from farmer-filmmakers in Japan and Mali to a gardener-filmmaker in Massachusetts, and from filmed landscape-portraits of women in Los Angeles, Orkney, and the Navajo Nation to Indigenous documentaries about land dispossession in Colombia. Proposing "land cinema" as an urgent genre for our time, this book reveals how images and ideas produced half a century ago sowed the seeds for climate justice movements today. Becca Voelcker is Lecturer in the Department of Art at Goldsmiths, University of London. She was named a BBC New Generation Thinker in 2024. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube Channel: here Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/environmental-studies

This week, we're joined by comedian Keysha E for a fun, slightly chaotic, and very honest conversation about dating, attraction, and figuring out what we actually want. From celebrity crush debates to whether chemistry is just a toxic addiction (yes, we said it), we get into the difference between a good partner and a good time.We also talk about pretty privilege in comedy, dating in Atlanta vs. LA, finances in relationships, and why “safe” might not be as boring as it sounds. Plus, we answer a listener question about feeling lost in life and share a CockTales story that involves a FaceTime mishap you absolutely don't want to experience

1. California's Wildlife Bridge and Homeless Crisis Guest: Jeff Bliss Summary: Jeff Bliss examines a $100 million wildlife bridge that is significantly over budget. He also details the "homeless industrial complex" in Los Angeles, including reports of signature fraud and billions in missing state funds. (1)1828 SPRINGERS

BTS. Alex Isley. Dubstep-infused hyperpop from underscores. NPR Music's Hazel Cills chats with Francesca Harding of member station KCRW in Los Angeles about their favorite albums out Friday, March 20. Plus, a handful of NPR Music writers and critics offer personal picks in our lightning round.The Starting 5(00:00) Introduction & BTS, 'ARIRANG'(02:28) Alex Isley, 'When The City Sleeps'(07:52) underscores, 'U'(15:38) ZENA, 'TEMESGEN'(20:39) Grace Ives, 'Girlfriend'(26:16) Suitor, 'Saw You Out With The Weeds'(32:23) The Lightning Round- Ali & Charif Megarbane, 'Tirakat'- Naomi Scott, 'F.I.G.'- Samara Cyn, 'Detour' EP- Immanuel Wilkins Quartet, 'Live at the Village Vanguard, Vol.1'- Luke Combs, 'The Way I Am'Sample the albums via our New Music Friday playlist and see our Long List of notable releases on NPR.orgCredits:Host: Hazel CillsGuest: Francesca Harding, KCRWAudio Producer: Noah CaldwellDigital Producer: Dora LeviteEditors: Otis Hart, Elle MannionExecutive Producer: Suraya MohamedSpecial thanks to Rodney Carmichael, Ann Powers and Stephen ThompsonTo manage podcast ad preferences, review the links below:See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Have you ever wondered if SEL (social and emotional learning) in school and classrooms really matters? I've been exploring this question a lot about over the past year, as well trying to understand the recent increase in parental and political pushback in the US specifically that is putting the future of SEL in schools at risk.   I wanted to get into a deep conversation about SEL for the show, and so I reached out Dr. Joseph Lee, a psychiatrist with a special interest in social and emotional learning and helping people achieve what he calls optimal mental healthiness. We had exactly the conversation I was hoping we would, as we got into so many important topics, including the state of children and young adult's mental health today, demystifying what SEL or social emotional learning actually is, why SEL matters, how it's best introduced in schools, the limitations in the current educational model for social emotional learning curriculums, what the pushback against SEL is really about, and what it's at stake if our children aren't provided with social and emotional learning opportunities. I think this is such an important and timely conversation – I hope that you enjoy it and that you help me amplify this episode by sharing it in your communities.   About Dr. Joseph Lee Dr. Joseph Lee, MD., is a Psychiatrist in private practice in Redondo Beach, California. He is also an educator in social and emotional learning (SEL) and provides individual and group supervision to licensed therapists looking to add mental healthiness and SEL principles to their own practices. Dr. Lee has a medical doctorate from University Of California, Los Angeles, School Of Medicine.   Key Takeaways Dr. Joseph Lee's thoughts on the state of children and young adult's mental health today What SEL or social emotional learning actually is and why it matters Ways that SEL can be weaved into traditional educational curriculum, as well as the use of specific SEL curriculum What social and emotional learning inside schools looks like in practice The “why” behind the pushback against SEL in the recent years and what's it's at stake if we lose the ability to teach SEL in classrooms  Resources Mentioned Mental Healthiness / Dr. Joseph Lee's website Collaborative for Academic, Social, and Emotional Learning Dr. Joseph Lee & Mental Healthiness on Facebook Dr. Joseph Lee on Twitter Hiding in Plain Sight: Youth Mental Illness (Ken Burns documentary) Daniel Goleman Emotional Intelligence: Why it Can Matter More Than IQ by Daniel Goleman Social Intelligence: The New Science of Human Relationships by Daniel Goleman U.S. Surgeon General Issues Advisory on Youth Mental Health Crisis Further Exposed by COVID-19 Pandemic Parenting the New Teen with Dr. John Duffy (Tilt Parenting Podcast episode) Learn more about your ad choices. Visit podcastchoices.com/adchoices

A whistleblower at the L.A. County Office of Emergency Management (OEM) filed a complaint alleging a colleague with a history of sleeping on the job was in charge of emergency workers sending evacuation alerts during critical moments of the Eaton Fire. LAist Climate and Environment Senior Reporter Erin Stone breaks down the complaint, what happened at OEM when the January 2025 fires broke out, and the serious concerns raised about OEM’s preparedness for the next big disaster. Read Erin’s full report at LAist.com. Grow your business–no matter what stage you’re in. Sign up for a one-dollar-per-month trial period at SHOPIFY.COM/paradise Support for this podcast is made possible by Gordon and Dona Crawford, who believe that quality journalism makes Los Angeles a better place to live.

A whistleblower at the L.A. County Office of Emergency Management (OEM) filed a complaint alleging a colleague with a history of sleeping on the job was in charge of emergency workers sending evacuation alerts during critical moments of the Eaton Fire. LAist Climate and Environment Senior Reporter Erin Stone breaks down the complaint, what happened at OEM when the January 2025 fires broke out, and the serious concerns raised about OEM’s preparedness for the next big disaster. Read Erin’s full report at LAist.com. Grow your business–no matter what stage you’re in. Sign up for a one-dollar-per-month trial period at SHOPIFY.COM/paradise Support for this podcast is made possible by Gordon and Dona Crawford, who believe that quality journalism makes Los Angeles a better place to live.

This week the boys are back to discuss the action for the week in the squared circle. The 1 count is WWE. Brock Lesnar gets an answer to his open challenge in Oba Femi. Randy Orton listening to an unknown person on the phone and the voices in his head as he turns heel on Cody Rhodes. Roman Reigns and CM Punk battle on the mic again. Drew McIntyre "quits" WWE long enough to return and screw Jacob Fatu in the SmackDown main event. The 2 count is a deep dive into the AEW Revolution card from Los Angeles. Returns and surprises galore. MJF retains over Hangman Page. What does this mean for Page? New women's tag champs are crowned. On Dynamite we hear from MJF post Revolution. Swerve makes Kenny Omega a counter offer to their match. Darby Allin vs Gabe Kidd in a Coffin Match. The 3 count is another attempt by JCB to make the boys jealous for missing NXT with a quick review of the show. Odds and ends to close things down! Available on all audio podcast platforms. Listen Share Subscribe Repeat! Rate and review on Apple and Spotify! WWE AEW 35:03 NXT 1:52:20

John Harris and Marc Vandermeer break down the 2026 schedule possibilities and air a powerful Azeez Al-Shaair interview on Friday's Texans All-Access. In this episode: * Azeez Al-Shaair sits down with John Gruden — shares his journey from homelessness in Tampa to Pro Bowl linebacker, his grandfather the poet laureate, tearing his ACL at FAU, and going undrafted * 2026 schedule either/or — should the Cowboys opener kick off the 25th anniversary season at NRG? * Best road trips: Green Bay vs. Los Angeles, toughest December games, and Monday Night Football picks * Joe Burrow at home vs. Jalen Hurts in Philly — which is the tougher matchup? * Free agency primer — a rapid-fire recap of every major Texans signing and trade this offseason * Wyatt Teller, Braden Smith, Ed Ingram, David Montgomery, Foster Moreau, Reed Blankenship, and more

⌛ Why Some Divorces Take Longer Than Others | Los Angeles Divorce Many people are surprised by how long divorce can take in Los Angeles. This video explains the minimum six-month waiting period required by California law, what actually causes divorces to drag on longer than necessary, and how most delays can be avoided with proper preparation.

✅ How to End a Marriage Legally Without Complications | Los Angeles Divorce Many people assume the easiest divorce comes from shortcuts—but in reality, it comes from cooperation. This video explains why mutual agreement makes ending a marriage legally simpler in Los Angeles, how clear terms reduce unnecessary steps, and why accurate paperwork turns agreement into court approval.

A Los Angeles radio show prank-calls random French citizens and unintentionally reach le président. A hotheaded comedian gets into a fight. Plus, a seven-year parking spot war. The French ConnectionA Los Angeles radio show prank-calls random French citizens and unintentionally reach le président. A very big thank you to Ralph Garman & Kevin Ryder for sharing their story with Snap! Radio rules.Produced by Max Jungreis, original score by Renzo Gorrio, edited by Nancy López + Anna Sussman. Choke ZoneMoshe Kasher tells a little story about conflict resolution. Thank you, Moshe, for sharing your story! Check out Moshe's memoir: Subculture Vulture: A Memoir in Six Scenes Produced by David Exumé, original score by Clay Xavier.The Parking Space WarA seven-year vendetta stemming from a parking spot war. Told live at the Black Cat by DC Benny.Thank you DC Benny for sharing this story! Big thanks also to 800 Pound Gorilla Media. Follow DC Benny at... Instagram, Facebook, X, TikTok, or on YouTube. Stay Connected with 800 Pound Gorilla -- check out their Instagram, Facebook, X, TikTok, or on YouTube.Season 17 - Episode 11 Learn about your ad choices: dovetail.prx.org/ad-choices

Today's episode will change how you think about your entire life. Because today you're meeting a top cancer surgeon who's going to help you think about one of life's big questions - the kind you don't usually ask yourself because you're just too busy: What really matters in life? Maybe you've been feeling off. Like you're doing a lot… but you're not sure it's the right stuff.  Maybe you're craving clarity… what to focus on and what to stop wasting your time on. Well that's the kind of guidance you're getting today. In this powerful conversation Mel is sitting down with Dr. Rahul Jandial, MD, PhD - a world-renowned cancer neurosurgeon and neuroscientist - who has treated and operated on more than 15,000 stage 4 cancer patients at the end of their lives. So in this conversation, you'll hear what becomes clear when time is running out: - What people wish they'd done sooner - What they wish they'd stopped caring about - What matters - and what never mattered at all - And the number one regret he hears from his patients again and again You'll also learn why so many of us wait until it's almost too late to start living the life we want… and how to change that - starting today. Dr. Jandial is the Medical Director of Neurosurgical Oncology and Skull Base Surgery at City of Hope in Los Angeles, one of the leading cancer centers in the world. He operates on brain cancers and spinal tumors in both adults and children, and directs a research lab focused on developing cutting-edge neuroscience and cancer treatments. Dr. Jandial has also lived through unbelievable twists and turns - from college dropout, to security guard, to becoming one of the most respected surgeons in the world - and today he shares what reinventing his life taught him about going after more and trusting yourself. In this episode, he will teach you how to find your footing again and build the kind of strength that will get you through any setback. What Dr. Jandial reveals in this episode is something he's never shared on any podcast. In this episode, you'll learn: - A simple daily practice that helps you remain steady, no matter what's happening - How to handle bad news without spiraling or panicking - What to do first when you're overwhelmed and don't know what to focus on - How to bet on yourself even when other people don't understand it - How to stop waiting for “someday” and start showing up more fully right now This conversation will shift your mindset so you stop waiting for ‘someday' and start showing up more fully right now. Because once you hear it, you'll see your life and the world differently. For more resources related to today's episode, click here for the podcast episode page.   If you liked the episode, check out this one next with Dave Evans and Bill Burnett: How to Design Your Life in 1 Hour Connect with Mel:     Order Mel's new product, Pure Genius Protein Get Mel's newsletter, packed with tools, coaching, and inspiration. Get Mel's #1 bestselling book, The Let Them Theory Watch the episodes on YouTube Follow Mel on Instagram  The Mel Robbins Podcast Instagram Mel's TikTok  Subscribe to SiriusXM Podcasts+ to listen to new episodes ad-free Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Two Hot Takes host, Morgan, is joined by guest co-host Spotify's very own Xavier Jernigan aka AI DJ X! We get into an assortment of stories where people's true colors are coming out. From someone who doesn't want to take care of their partner when sick, to a weird family initiation OP wants their partner to participate in, to someone who heard their partners family talk terribly about them.. these are some complicated ones. Going to need your takes on these too!  Checkout X's IG: https://www.instagram.com/xavierjernigan/?hl=en Partners: Duluth Trading Company: Shop at DuluthTrading.com and in-store today.  Skims: Skims.com Patreon BONUS Content including FREE stories: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/TwoHotTakes ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ NEW MERCH:  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://shop.twohottakes.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Send us a letter? Our PO Box!! Two Hot Takes. 5042 Wilshire BLVD. #470. Los Angeles, CA 90036  WRITE IN TO US!!! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://reddit.app.link/twohottakes ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Full length Video episodes available on YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/c/TwoHotTakes⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Index: 00:00 -- Start Learn more about your ad choices. Visit podcastchoices.com/adchoices

Actor Alan Tudyk (Arrested Development, Rogue One, Resident Alien) and comedian and actor Jade Catta-Preta (Modern Family, Life in Pieces, The Soup on E!) join Jameela for an episode that somehow ends up exactly where you'd expect, and nowhere you could have predicted.Alan's micro humiliation arrives courtesy of a chance encounter with a Disney executive, a case of mistaken identity, and the particular horror of confidently addressing the wrong powerful man by the wrong name to his face. His Big Wrong Turn takes us to a casual industry football game, where Alan shows up with brand new boots bought the day before, immediately starts playing what can only be described as rug-ball, gets demoted to goalie, concedes three goals, and is the only person in Los Angeles not invited for drinks afterwards.Jade's micro humiliation unfolds live on Watch What Happens, when an attempt to remove a stray hair from Andy Cohen's face reveals that it is very much still attached to him. Her Big Wrong Turn takes us back to a school production that cemented her fate as the default ethnic casting choice for every role going, from Lola in Damn Yankees to Scary Spice, not because she was the best fit, but because she was the only brown person in the building.In place of this week's Misery Loves Company, Jameela shares the story of paying for a friend's IVF to avoid becoming a godmother, only to watch that friend meet her sperm donor the night before the procedure and immediately render the whole thing completely unnecessary.Watch Alan Tudyk in Resident Alien on Sci-Fi and Peacock, and in Superman. He also co-hosts Once We Were Spacemen with Nathan Fillion, available wherever you get your podcasts. Follow Jade Catta-Preta at @JadeCattaPreta across socials, catch her live in New York and Alaska in July, and find her on OnlyFans at @FunnyButt.Jameela's Substack is A Low Desire To Please, you can also find her on Instagram, TikTok and YouTube.Our consulting producer is Colin Anderson.Wrong Turns was created and produced by Jameela Jamil and Stewart Bailey. Hosted on Acast. See acast.com/privacy for more information.

It was August 22, 1922, in Los Angeles, and German immigrant Fred Oesterreich was in the middle of a heated argument with his wife, Walburga “Dolly” Oesterreich. Without warning, when Fred turns around he's face to face with a man he knew a decade ago, back in Milwaukee, and he's holding two pistols. Fred didn't hear the man come in, and most importantly, why was he here in the first place!?  Check out Patreon and our other shows!: Patreon.com/truecrimeguys Cryptic Soup w/ Thena & Kylee Strange & Unexplained True Crime Guys YouTube EVERYTHING TRUE CRIME GUYS:   https://linktr.ee/Truecrimeguysproductions True Crime Guys Music: True Crime Guys Music on Spotify OhMyGaia.com Code: Crimepine Patreon.com/truecrimeguys Patreon.com/sandupodcast Merch: truecrimeguys.threadless.com   Sources: Book: “The Most Bizarre True Crime Stories Ever Told” by Jack Rosewood https://strangeco.blogspot.com/2013/12/ottos-in-attic-or-hell-dolly.html https://historic-horrors.com/2025/05/22/the-man-in-the-attic-a-forgotten-crime-of-passion-from-los-angeles-roaring-twenties/ https://www.reddit.com/r/todayilearned/comments/5t1qis/til_an_la_woman_hid_her_lover_in_the_attic_for/ https://www.atlasobscura.com/articles/the-married-woman-who-kept-her-lover-in-the-attic https://www.youtube.com/watch?v=iGu6ZdWM2Wg&t=581s

Across the country, photojournalists, videographers, live steamers and other documentarians are telling the story of resistance to ICE. They do this at great personal risk, both physical and legal. In our latest, we talk with movement photojournalists Brooke Anderson and Rae Breaux about their work in telling the story of anti-ICE movements, as well as many other movements, in the Bay Area and Los Angeles, and how other documentarians are doing it across the country. This is an episode about getting the shot, staying safe and defending a free press. Bios//Rae Breaux is an organizer, trainer, and movement photographer based in Los Angeles, CA. She has over fifteen years of experience developing intersectional, cross-movement strategies around race, class, gender, and the systemic drivers of the climate crisis. Rae has a strong background in coordinating and implementing creative actions, building cross-issue coalitions, and using photography and the power of imagery to create narratives and tell the stories of people and the planet. She is on Instagram at @craezin.Brooke Anderson is longtime organizer turned freelance photojournalist based in Oakland, CA. She covers movements for social, economic, racial, and ecological justice. Her most recent work can be found in Prism, Convergence Magazine, YES! Magazine, Teen Vogue, In These Times, and Earth Island Journal. She is a proud member of the Pacific Media Workers Guild, CWA 39521. She is on Instagram at @MovementPhotographer.---------------

Here comes Oba! Reactions from WWE's Monday Night Raw including Oba Femi's destruction of Brock Lesnar. What's next for "The Ruler"?! Plus, the verbal jousting between CM Punk and Roman Reigns becoming physical, Becky Lynch attacks AJ Lee after her title defense against Bayley, and what will come of Randy Orton's heel turn? O'Shea and TJ also react to this past weekend's AEW's "Revolution" from Los Angeles. FTR v. The Young Bucks, the return of Cage and Cope, a bloody battle between MJF and Hangman Page, and a return to wrestling for Ronda Rousey? Learn more about your ad choices. Visit podcastchoices.com/adchoices

This week on The Leftovers, never-before-heard audio from Padma Lakshmi, Emmy nominated TV host, executive producer, best-selling author and activist. Padma hosted Top Chef for 17 years and her brand new show, America's Culinary Cup, recently premiered on CBS.   In this week's lightning round, Padma talks about how she decides whether to eat the food fans bring her at meet-and-greet events; what she ate as a 16-year-old teenager in Los Angeles; what the ultimate New York City food is and her perfect birthday dessert.  Listen to the full episode of Your Last Meal with Padma Lakshmi here! Become a Cascade PBS member and support public media!   Watch Rachel's Cascade PBS TV show The Nosh with Rachel Belle. Sign up for Rachel's (free!) biweekly Cascade PBS newsletter for more food musings. Follow along on Instagram. Order Rachel's cookbook Open Sesame. 

Given the ongoing turmoil in the Middle East, President Trump has taken bold action to unleash oil production in California. But Gavin Newsom and his cronies are determined to block him. Why are Democrats prioritizing political battles while Californians suffer at the gas pump? Steve breaks it all down and highlights the other ways the federal government is stepping in to save the state from itself. Then, Susan Shelley joins the show with eye-opening details on California's runaway healthcare spending, Newsom's “Cap-and-Invest” environmental scheme, and the growing trend of streetlight vandalism in Los Angeles. And finally, Rhetor AI co-founder Jeremy Jones stops by to discuss his “government efficiency” technology and how it's being used to help CAL DOGE identify waste and fraud.

In this episode, we sit down with Robert Hartwell, a former Broadway performer turned entrepreneur, to explore his powerful journey from the stage to building a successful business. Robert shares how discovering theatre at just seven years old sparked a lifelong passion for the performing arts—and how that moment shaped his vision-driven life. Backed by a strong support system, including his family's unwavering belief in his dreams, he developed the confidence to pursue success without limits. We dive deep into the mindset and persistence required to succeed, including how Robert secured a full scholarship to Stagedoor Manor through determination and bold action despite financial challenges. Robert also opens up about the realities of entrepreneurship, including navigating business setbacks during the pandemic, making tough decisions, and learning how to pivot and rebuild stronger. This episode is packed with actionable insights for entrepreneurs, creatives, and anyone looking to turn their passion into a profitable business. If you're looking to build resilience, develop a success mindset, and take consistent action toward your goals, this episode is a must-listen. If you would like some help with figuring out how to transform your life! I can help you create a vision for a life that you absolutely love living. Click here to arrange a session with me. If you're enjoying the podcast, please share the show with a friend or, even better, leave a review to ensure others can benefit from it too! Don't Stop at The Happy Hour Event, Happening on March 20th at the  Gathering Spot in Los Angeles.  FIND MORE ABOUT ROBERT HARTWELL Robert's - website and instagram WHAT YOU'LL LEARN FROM THE EPISODE Early experiences in life shape our long-term success The importance of taking small, consistent actions towards achieving one's goals.  The importance of having a supportive community around you during the seasons of building your life. Adversity often acts as a stepping stone to greatness. FEATURED ON THE SHOW: If you're enjoying the podcast, I'd love to hear from you! Please share the show with a friend or even better, leave a review to ensure others can benefit from the podcast.

Dr. Monty Pal and Dr. Vamsi Velcheti discuss the evolving treatment landscape in EGFR-mutated non-small cell lung cancer, including landmark trials like FLAURA2, novel drug therapies, and the growing importance of ctDNA and MRD testing. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, I'm truly delighted to introduce Dr. Vamsi Velcheti, who's a professor of medicine and the chief of hematology-oncology at the Mayo Clinic in Jacksonville, Florida. We'll be discussing the expanding treatment landscape in EGFR-positive lung cancer and how to navigate the challenges of balancing treatment efficacy, toxicity, and patient quality of life in the EGFR-positive space.  Just FYI, our full disclosures are available in the transcript of this episode.  Vamsi, it's so great to have you on the podcast. Thank you so much for being here. Dr. Vamsi Velcheti: Thank you, Monty. It's a pleasure to be here with you. It's a really exciting topic and there are a lot of updates in the EGFR space. Dr. Monty Pal: So, I'm going to need your help with this because I'll be honest with you, I see very little lung cancer, if any, in my practice. I'm pretty much exclusively kidney cancer these days. I'm coming on 20 years at City of Hope now, and I still remember when trials like ECOG 1599 were presented with, you know, platinum doublets. And, of course, the field has changed a lot since then. But tell us a little bit about the first-line landscape, and I think just for the sake of time, we're going to stick with EGFR-positive disease here. What does it look like these days? Dr. Vamsi Velcheti: Monty, the foundation of care remains the third-generation EGFR inhibitors. These are selective EGFR inhibitors, like osimertinib. We've had an evolution of the development of these TKIs. Like, you know, we had the first-generation, second-generation, not-so-selective EGFR inhibitors. Now we have mutant-selective EGFR inhibitors in the clinic, and they're doing a really good job. And these are quite effective in patients who have classical activating mutations. But the reality is that these have not been transformative. These agents have fundamentally changed the response patterns, excellent CNS penetration, and very good tolerability profile. However, we don't see a lot of durability in terms of the response. So, what's different today is now there have been several trials in combination with these third-generation EGFR inhibitors that have really laid the foundation of how we kind of think about EGFR-positive disease. At the high level, there are a lot of challenges to selecting the patients for these combination-based modalities. I'm assuming we'll be talking more about these different trials and different approaches. Some of these combination-based strategies have really moved the needle in terms of improving overall survival and really improving long-term outcomes and durability in our patients. Dr. Monty Pal: And we are going to get into the weeds on this in just a moment. But I did kick off this podcast talking about chemotherapy, ECOG 1599. It does seem as though chemotherapy is still a component of management in advanced non-small cell lung cancer. So, can you tell us about, perhaps first, you mentioned osimertinib, you know, some of these next-generation EGFR inhibitors. Tell us about the role of chemo plus osimertinib. Dr. Vamsi Velcheti: That's exactly where I was going with the combination-based strategies. You know, we first started off with our earlier trials in the EGFR space evaluating the question of, are targeted therapies, are these highly effective, third-generation, EGFR-selective inhibitors, superior to platinum-doublet chemotherapy? And we've had multiple trials demonstrating that, like the FLAURA trial and in the past with second-generation EGFR inhibitors like erlotinib and gefitinib and afatinib. So, we know that these TKIs actually perform better than platinum-doublet chemotherapy. Now, we have a large, global, phase 3 trial data from the FLAURA2 trial, which looks at the question, "Hey, you know, osimertinib is better than chemotherapy, platinum-doublet chemotherapy. Can we do even better by combining osimertinib with platinum-doublet chemotherapy?" So, FLAURA2 answered that question. This is a large, phase 3 trial, and it's a positive trial with improved durability of disease control and improving overall survival with combination with chemotherapy. So, it's a very important and landmark trial, and essentially combining osimertinib with a platinum-based chemotherapy improved responses, deepened responses, and improved overall survival and really changing the disease trajectory. And this strategy is definitely compelling, especially in patients who have certain clinical high-risk features like, you know, patients who have high disease burden or patients who are sometimes having rapid disease progression early on osimertinib, especially with patients who have a lot of visceral disease burden. So, intensifying treatments up front could alter the natural trajectory of the disease. Dr. Monty Pal: So, you sort of alluded to this in that last part there, but is that kind of how you in clinical practice select? Is it based on, you know, visceral involvement? Is it based on rapidity of disease where you think about adding chemotherapy to osimertinib? Maybe you can give us the corollary. Which patients do you just use osimertinib alone in, for instance? Dr. Vamsi Velcheti: Definitely, there are some patients who have low disease burden and they have the classical mutations, like an exon 19 deletion. And these patients, especially if they don't have a lot of disease burden, they don't have CNS involvement, there may be a subset of patients who could just do fine on osimertinib of course, with close monitoring of the disease. I guess we'll get into that later, how do we do that with either ctDNA or like closer imaging or both. So, there may be some opportunity to kind of escalate patients' treatments based on certain clinical characteristics or radiographic characteristics or certain biological characteristics informed by ctDNA or other approaches. Dr. Monty Pal: No, that's interesting. And you're right, we will chat about ctDNA in just a bit. But before we get there, I think one of the big agents that has really sort of come to the fore in advanced non-small cell lung cancer is amivantamab. I've heard a lot about this in the context of even kidney cancer because in certain subsets, I'm interested in MET-directed therapies and so forth, right? So maybe tell us a little bit about the mechanism of amivantamab first, and then maybe tell us about this pivotal MARIPOSA trial where it's combined with lazertinib. Dr. Vamsi Velcheti: So, the MARIPOSA trial compared lazertinib alone with amivantamab plus lazertinib. And this trial demonstrated overall survival advantage, and there were key differences in terms of tolerability and the safety of amivantamab, which is an EGFR and MET bispecific, and there were certain kind of unique toxicity profiles that make it a little different than the intensification approach with chemotherapy through the FLAURA2 trial. So, there's a trade-off in terms of the toxicity profile. It's a different agent and a different management protocol in terms of dermatological toxicity management that clinicians need to be comfortable with. And also, there are certain unique issues in terms of amivantamab; there's a higher rate of infusion-related reactions, there's an increased risk for edema and VTEs because of amivantamab. Certainly a different toxicity profile, different management paradigm there in terms of longitudinal care of these patients requiring dermatological care and like, you know, close monitoring and prophylaxis VTEs. But having said that, definitely it's a different strategy, and it kind of changes the biology and the natural history of the cancers, and we do see some durability of responses that we see with the MARIPOSA. So, it's certainly a great alternative, at least for some patients. Dr. Monty Pal: That was a great overview of MARIPOSA. Now comes the really difficult question, which is, how do you choose between the two? You have these two great options, right, for EGFR-positive patients. You've already highlighted some of the distinctions in terms of toxicity. I think the audience is well aware of the side effects of chemo-doublet, perhaps even the EGFR-based therapies. Amivantamab is quite new. Give us a sense of how you in clinical practice decide between the two potential options here. Dr. Vamsi Velcheti: Yeah, I think that's the big challenge. I think these are two independent strategies that have evolved through the phase 3, and both of them have demonstrated overall survival benefit. So, the way I think about this is in three dimensions, right? Like, the disease biology, the patient priorities, and feasibility of care delivery. So, when I talk about the disease biology, you know, the mechanism is very different, and MET is a very dominant driver of disease in EGFR-altered patients and it's a significant mechanism of resistance, acquired resistance to TKIs. So, certainly I think there's a patient population that could benefit from a MET-directed therapy up front. However, we don't have great data to kind of really demonstrate how using amivantamab in the front line is going to change that. And are there like perhaps like some patients who we could identify who would benefit from such a strategy? Very recently, there have been some approvals in the second-line setting in lung cancer, not in the EGFR space, but like in generally in lung cancer, with the MET ADCs, and those drugs are approved with a companion diagnostic, which requires MET IHC testing. So, what has happened, at least in large academic practices and also I think in the community now, they have been checking for MET IHC expression more routinely in lung cancer. What we have been doing in our institution is we have been doing MET IHC as a reflex for all patients with EGFR, not just EGFR, but all non-small cell lung cancer patients. What that has done is now, like, we have been increasingly testing patients with EGFR for MET. And there's clearly a subset of patients who have de novo MET expression and a high MET expression. And those patients, I've been kind of like preferentially treating them with the MARIPOSA regimen. But again, I have to caution the audience that we still don't have data that MET IHC is going to help us make those decisions, whether it's better than like a FLAURA2 regimen. But however, in the second-line setting in the CHRYSALIS trial, we know that MET is a very powerful predictor of response to amivantamab. We really need more data there, but that's what I have been doing in my practice. But also, there's a lot of patient preference here. Like, there are some patients who don't want chemotherapy, and they want a non-chemotherapy approach. So, certainly there are some patients who prefer to have amivantamab. And now with the amivantamab, the subcutaneous version, the infusion reactions and the logistics of actual administration of amivantamab are more favorable with the subcutaneous approval. So, those are some of the elements that we need to take into account. Dr. Monty Pal: Well, I want to hone in on that because this subcutaneous administration route has been a big debate that I've seen on social media. Tell us, how much easier does it actually make the amivantamab experience? Does it cut down on the rash? Is it just infusion reactions? What's been your clinical experience? Vamsi Velcheti, MD: So, the subcutaneous administration of amivantamab has definitely improved the infusion reaction issue. Very rarely patients have infusion reaction now with the subcutaneous injections. And also, the infusion time is much, much shorter. Like we don't need a lot of infusion time, which is sometimes a challenge in busy infusion clinics. We need to take that into account. As far as the impact of the subcutaneous formulation on dermatological toxicity, we haven't really seen significant difference in terms of the intensity or rates of dermatological toxicity with subcutaneous. The benefits are really with the infusion reaction, the ease of administration. And interestingly, in the PALOMA trial, it also seems to be, even though this was not the primary endpoint of the study, there seems to be some suggestion that the subcutaneous amivantamab seems to have improved OS compared to the IV amivantamab. We don't really understand why, but that's a finding from the trial that's very intriguing. Dr. Monty Pal: That is really fascinating. I'm kind of curious to see how that's going to pan out. I'm going to shift gears a little bit here. And, you know, as we sort of close, I wanted to talk a little bit about biomarkers. I mean, this is obviously not a lung cancer-specific issue. It's something we think about across the board. But what I will say is that there are certain commonalities, and in bladder cancer, we think a lot now about ctDNA. But you've been way ahead of the game in lung cancer. Tell us how you guys use ctDNA, maybe both from the standpoint of monitoring for mutational status, but if you can, maybe offer some insights into some of these new MRD tests that are available too. Dr. Vamsi Velcheti: Yeah, it's rapidly evolving. Certainly, I think in the lung cancer space, you know, this has really kicked off in the lung cancer space with incorporating ctDNA into the workflow. Of course, you know, like baseline evaluation, we still kind of heavily rely on tissue genomic sequencing. But as you know, with targeted therapy, a lot of these patients have disease that evolves over time, and changes in terms of mutational pattern driving acquired resistance is a major issue across different molecular subtypes. And especially so in EGFR, when there are certain actionable opportunities associated with that transformation. So, we need to kind of have like a longitudinal snapshot of how we monitor these patients. So, the ctDNA has come to be like a tool that has now come to the forefront of clinical workflow, and almost all my patients who are having disease progression have ctDNA for kind of evaluating for resistance and informing treatment decisions, especially in EGFR. But having said that, there are a lot of challenges in terms of using ctDNA as a tool for monitoring. There are a lot of different types of assays and different platforms, and being able to use this as a quantitative tool that would be used along with the CT scans that we routinely use in clinical practice has been a challenge. And I think I would love to hear your perspectives as well, Monty, about how you're thinking about that in bladder and other disease contexts. But having said that, I think there's a lot of opportunity to incorporate ctDNA and MRD assays into clinical decision-making. Right now, in terms of clinical trials and clinical development, there have been some very interesting trials that are currently ongoing, especially in the EGFR space. We know that patients who clear ctDNA, based on some retrospective data and also like some retrospective-prospective data from trials that have already read out, that patients who clear ctDNA early with target therapy tend to do much better. They have a longer durability of response. There may be a subset of patients who have, even though they're having radiographic response, they have persistent ctDNA after a certain time point of initiation of targeted therapy. Those patients may require escalation of therapy. We don't yet know. I can't recommend that as a standard right now because we don't have clinical evidence to support that. But however, some of the clinical trials, like the ELIOS trial that's being done right now, that's actually completed enrollment, we'll hopefully see the results very soon. So, there is an emerging thought that instead of intensifying treatment for all patients with EGFR, there may be a population that may be just fine with frontline osimertinib monotherapy and introducing the intensification strategy at the time of emergence of MRD or progression on ctDNA before radiographic progression. So, there are a lot of adaptive molecular response criteria that we are kind of exploring in clinical trials that could inform how the future is going to look like for EGFR and other perhaps targeted therapies as well. So, it's fascinating, and I think there's a lot of opportunity there. Dr. Monty Pal: You know, you asked for my perspective. I actually think that what you highlighted there is the most interesting opportunity for ctDNA: the ability to de-escalate therapy. In terms of drug development, we've done so much to bring new therapies to patients, and now it's a bit of an embarrassment of riches, but the downside is that I feel like we tend to overtreat a lot of patients in the clinic. So, I definitely view MRD, you know, some of these other ctDNA techniques with methylation and so forth that may not be sort of tumor-dependent or bespoke could be incredibly, incredibly helpful. You touched on sort of the future, right, in this last section here with biomarkers. But give us a sense now in terms of novel drug therapies in the EGFR space. What are you most excited about moving forward in 2026 and beyond? Dr. Vamsi Velcheti: Yeah, I think there's a lot going on in this space, and not just this space, but across lung cancer and others as well. Like looking at the next generation of targets for ADCs. And I think a lot of these have to do with…so far in the drug development space, as you know, the improvements in clinical outcomes has been very incremental. So, we really need to make that big leap. And I think the big leap is not going to come from, in my opinion, from the next ADC, but it's going to come from how we tailor treatments and how we monitor disease better and how do we kind of incorporate the next treatment earlier and not wait for the radiographic progression. So, there's a lot of opportunity there to integrate biomarkers and dynamic biomarkers into clinical trial design and incorporating the recent advances in terms of drug design. You know, we have a lot of assets in the EGFR space, the next-generation EGFR inhibitors that are kind of designed with resistance in mind and rational combination, knowing when to introduce those combinations is also equally important. So, there's a lot going on, really exciting times to be in drug development. The one thing that I really hope will come to the forefront in drug development, not just for lung cancer, but all disease groups, is to kind of really be thoughtful about how we incorporate these really cool molecular monitoring tools and creating a composite score with imaging to be able to like really design the next generation of clinical trials. Dr. Monty Pal: You're so spot-on with that. I definitely think that we're getting to this point where, you know, we could think about the next BiTE, the next CAR-T, the next ADC. But, you know, maybe it's time for us to start really honing in on appropriate applications of these drugs, honing in on the right dose and what have you, because I definitely see some issues there.  Vamsi, this has just been terrific. I really want to thank you so much for sharing your fantastic insights with us today on the ASCO Daily News Podcast, and I really appreciate all your efforts to move the field of lung cancer forward. Dr. Vamsi Velcheti: Thanks, Monty. I really enjoyed the conversation. Dr. Monty Pal: Yeah, this was terrific.  And thanks to our listeners as well. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Monty Pal   @montypal  Dr. Vamsi Velcheti @VamsiVelcheti Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Vamsi Velcheti:   Honoraria: Galvanize Therapeutics  Consulting or Advisory Role: Bristol-Myers Squibb, Merck, AstraZeneca/MedImmune, GSK, Amgen, Taiho Oncology, Novocure, Regeneron, Takeda, Janssen Oncology, Picture Health Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline

House Committee on Appropriations Subcommittee on Interior, Environment, and Related Agencies Date: Tuesday, March 18, 2026 – 1:00 PM Location: Capitol Complex, 2008 RHOB, Washington, DC, 20515, USA • LIVESTREAM: https://youtu.be/1iTI_qqEM3E Witnesses Panel one Cynthia Petersen President, Yakutat Tlingit Tribe Panel two Jarred-Michael Erickson Chairman, Confederated Tribes of the Colville Reservation Jeremy Takala Tribal Councilman, Confederated Tribes and Bands of the Yakama Nation Panel three Kristopher Peters Chairman, Squaxin Island Tribe Loni Greninger Vice-Chair, Jamestown S'Klallam Tribe Quintin Swanson Chairman, Shoalwater Bay Indian Tribe Robert de los Angeles Chairman, Snoqualmie Indian Tribe Panel four Guy Capoeman President, Quinault Indian Nation William (Bill) Iyall Chairman, Cowlitz Indian Tribe Louie Ungaro Councilman, Muckleshoot Indian Tribe Panel five Annette Bryan Councilwoman, Puyallup Tribe of Indians Panel six Derek Bowman Tribal Council Member, Bear River Band of the Rohnerville Rancheria Joe Davis Chairman, Hoopa Valley Tribe Panel seven Ed Johnstone Chairman, Northwest Indian Fisheries Commission Jon Panamaroff Co-Chair, Native American Contractors Association Ervin Carlson President, InterTribal Buffalo Council Cody Desautel President, Intertribal Timber Council Panel eight Mark Macarro President, National Congress of American Indians Ira L. Matt Executive Director, Indigenous Diplomacy and Federal Relations, National Association of Tribal Historic Preservation Officers Amy Minniear Treasurer, NAFOA More on Indianz.Com: https://indianz.com/News/2026/03/16/video-american-indian-and-alaska-native-public-witness-hearing-day-2-afternoon-session-2/

Bomani Jones is joined by Vinnie Goodwill to talk through the biggest NBA storylines right now. They break down what's going wrong with Kevin Durant and the Rockets, why Luka Doncic has the Lakers rolling, and whether Los Angeles can really survive with its defensive flaws. They also get into Victor Wembanyama's absurd impact, the Western Conference playoff race, LeBron's future in Los Angeles, and what NBA expansion could mean for the league. Learn more about your ad choices. Visit megaphone.fm/adchoices

Trump finds himself isolated on the world stage– and begging for help. Brian interviews Pod Save America's Dan Pfeiffer, Congressman Jamie Raskin, and legal journalist Adam Klasfeld.Subscribe to Message Box: https://www.messageboxnews.com/Subscribe to All Rise News: https://www.allrisenews.com/Shop merch: https://briantylercohen.com/shopYouTube: https://www.youtube.com/user/briantylercohenTwitter: https://twitter.com/briantylercohenFacebook: https://www.facebook.com/briantylercohenInstagram: https://www.instagram.com/briantylercohenPatreon: https://www.patreon.com/briantylercohenNewsletter: https://www.briantylercohen.com/sign-upWritten by Brian Tyler CohenProduced by Sam GraberRecorded in Los Angeles, CASee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mayor does his deep dive on the warm temperature records in Los Angeles. It is truly unbelievable that the state's DHS claims that it could not investigate kickbacks as a form of fraud. Robot goes crazy at CA restaurant. Johnny Heidt with guitar news. Heard On The Show:Lexington woman and boy killed in suspected double homicideGovernor's budget plan: Tax cuts for middle-class families, spending cuts to nursing homesGulf oil facilities evacuated after Iran threatSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

March 16, 1990. San Francisco County, California. 17-year old Toni Clark, who happens to be two months pregnant, leaves her cousin's residence in Oakland to drive back to her apartment in San Bruno in her boyfriend's Chevrolet Camaro. Shortly thereafter, the stalled Camaro is discovered on the Bay Bridge and after another motorist crashes into it, investigators conclude that Toni was likely propelled off the bridge into San Francisco Bay. However, Toni's body is never recovered and there are a number of odd discrepancies, such as reported sightings of a black male next to the Camaro shortly before the accident and a bizarre anonymous phone call to Toni's mother, which cause speculation that Toni was abducted. On this week's episode of “The Trail Went Cold”, we will explore whether Toni Clark was actually the victim of a tragic accident or if something much more sinister happened. In addition, we'll also discuss the unsolved disappearances of 28-year old Diego Garcia, 41-year old Carmen Burhans Garcia and eight-year old Barbara Burhans, who all vanished after leaving their home in Los Angeles in March 1982 before their abandoned car was discovered 250 miles away at the bottom of a gorge in the San Gabriel Mountains. Additional Reading: https://charleyproject.org/case/toni-danieelle-clark https://www.newspapers.com/image/1225351368/ https://www.newspapers.com/image/779247127/ https://www.newspapers.com/image/779247141/ https://www.newspapers.com/image/461548309/ https://www.newspapers.com/image/758981652/ https://www.newspapers.com/image/696741911/ https://www.newspapers.com/image/696741925/ https://www.sfgate.com/bayarea/article/The-Other-Missing-Kids-They-quickly-faded-from-2975456.php https://abcnews.com/Primetime/story?id=131955 https://www.newspapers.com/image/633633829/ https://www.newspapers.com/image/633633861/ https://charleyproject.org/case/diego-garcia https://charleyproject.org/case/carmen-maria-burhans-garcia https://charleyproject.org/case/barbara-aurora-burhans “The Trail Went Cold” is on Patreon. Visit www.patreon.com/thetrailwentcold to become a patron and gain access to our exclusive bonus content. The Trail Went Cold is produced and edited by Magill Foote. All music is composed by Vince Nitro.

Tom Haberstroh, Amin Elhassan and producer Anthony Mayes are still fiending for the Insights to Excellence from Michael Jordan that NBC has been trickling out since the beginning of the season. Truth Teller Jorge Sedano of ESPN is uniquely equipped to tackle Bam Adebayo's historical evening, being born and raised in Miami while currently doing radio in Los Angeles. We also talk NBA Expansion, test Jorge's knowledge of the Backstreet Boys catalog and discuss who Wemby should replace on his bookcase full of photographs. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Subscribe to the Illuminati YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Channel⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Basketball Illuminati is now part of the Count The Dings Network. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Join the Count The Dings Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to support the show, get ad free episodes and exclusive content at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/countthedings⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ILLUMINATI MERCH HAS RETURNED⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - Check it out here:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/CTDMERCH⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow Basketball Illuminati! On⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠basketballilluminati@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@bballilluminati⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@basketballilluminati⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Greg responds to the claim that there's no proof for God, then he answers questions about whether the parables in Luke 12 indicate salvation can be lost, Sarah sending away Hagar, how sin moved from an angel to a tree, and what it means to say Jesus took on the sins of the world.   Topics: Commentary: Where's the proof for God? (00:00) Are the parables in Luke 12 specifically directed at believers, and if so, don't they imply salvation can be lost? (27:00) Can you explain what the story about Sarah sending away Hagar means? (38:00) How did sin go from being within an angel to being within a tree in a garden, and did Jesus' taking on the sins of the world break some special power of sin for us, or was Jesus just taking away the consequences of sin? (45:00) Mentioned on the Show:  #STRask podcast with Greg and Amy History of Philosophy by Frederick Charles Copleston Reality Student Apologetics Conference – April 24–25 in Los Angeles, CA Submit a question on the Open Mic Line

Could one platform change your entire life? In this episode of Holly Randall Unfiltered, I sit down with Genna James, one of the fastest rising creators on Stripchat.Only six months ago, Genna was homeless in Los Angeles after losing housing at her dream art school and struggling to survive. Today she's building a rapidly growing audience online and turning her cam career into something that looks more like a full media brand.Genna opens up about how she went from couch surfing and sleeping in a community bodega to becoming financially independent through live streaming. We talk about how cam platforms actually work, why focusing on one site helped her grow faster, and what it really takes to build a successful room from scratch.It's an honest, funny, and surprisingly insightful conversation about resilience, online entrepreneurship, and the unexpected paths people take to build success.Want the unedited, uncensored live tapings + bonus Q&A where fans can ask questions? Join our Patreon.https://patreon.com/hollyrandallunfilteredThis episode is brought to you by Stripchat, the exclusive sponsor of Holly Randall Unfiltered.https://www.instagram.com/scworld.officialBecome a supporter of this podcast: https://www.spreaker.com/podcast/holly-randall-unfiltered--6630320/support.